Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

ABSTRACT:

Aims

REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.

Methods and results

A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary r

SUBMITTER: HPS3/TIMI55-REVEAL Collaborative Group 

PROVIDER: S-EPMC8986460 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature